(Q44463455)

3 December 2017

title

Reduction in mortality associated with statin therapy in patients with severe sepsis (English)

1 reference

3 December 2017

0 references

0 references

1 reference

Paul P Dobesh

1

1 reference

3 December 2017

Donald G Klepser

2

1 reference

3 December 2017

Timothy R McGuire

3

1 reference

3 December 2017

Craig W Morgan

4

1 reference

3 December 2017

Keith M Olsen

5

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

3 December 2017

1 reference

3 December 2017

volume

29

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

621-630

1 reference

Sepsis in the 21st century: recent definitions and therapeutic advances

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

The pathophysiology and treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Statins for infection and sepsis: a systematic review of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Statins and sepsis: multiple modifications at multiple levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

The endothelium, inflammation, and coagulation in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

The effect of statins on mortality in patients with bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

APACHE II: a severity of disease classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Statins and the vascular endothelial inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.6.621

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.6.621

1 reference

3 December 2017

1 reference